| 11.04.21 | Sangamo shares leap on early Fabry readout; Bayer nabs Otsuka vet for R&D revamp plan

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

3 jahre vor

Html
Text

Faster, Safer, Cheaper Study Start-Up. Guaranteed.

Modern trials need modern systems to manage data, meet regulatory demands, and make deadlines. Try Remarque Systems risk-free. If you are not happy within the first 3 months, we will apply a credit towards another product in our suite. Book a Demo Today.

Today's Rundown

Sangamo's Fabry gene therapy clears early clinical test, firing starting gun on preparations for phase 3 Bayer poaches Otsuka's chief medical officer Koenen to head up its clinical operations Amgen plays multi-specific matchmaker in quest to tackle the undruggable Sponsored: A New Reference Model for Clinical Trial Recruitment, Enrollment and Retention Success VC shop Mission BioCapital raises $275M 5th fund with focus on incubating startups Sponsored: Intranasals in Clinic Now Positioned for $71 Billion Nasal Delivery Market After flops, Ironwood starts pipeline rebuild with liver disease deal Pfizer adds to Parthenon's $65M war chest to back battle at the tumor barrier Aptose inks $408M biobucks deal with Hanmi for access to myeloid inhibitor Allara launches at-home hormone test for diagnosing polycystic ovary syndrome Turning CAR-T tech against solid tumors by targeting protein fragments in cancer cells ASH: Chasing AbbVie and J&J's Imbruvica, BeiGene's Brukinsa fleshes out competitive leukemia data again CMS: Healthcare workers must receive their first COVID vaccine by Dec. 5 to continue Medicare, Medicaid participation

Featured Story

Sangamo's Fabry gene therapy clears early clinical test, firing starting gun on preparations for phase 3

By Nick Paul Taylor

Sangamo Therapeutics has posted clinical data on a therapy it hopes will shake up the Fabry disease market. The gene therapy showed encouraging safety and efficacy signs in the small study, prompting Sangamo to start preparations for a phase 3 clinical trial.

Article: Finding Success with Metabolon

Learn how two leading biotech companies harnessed the power of metabolomics to guide drug development decision-making and advance their programs to the next phase of development. Download now!

Bayer poaches Otsuka's chief medical officer Koenen to head up its clinical operations

By Ben Adams

As Bayer looks to ramp up its R&D work in the gene therapy space amid a host of biotech tie-ups, the German pharma is tapping Christoph Koenen as its new global head of clinical development and operations in its R&D unit.

Amgen plays multi-specific matchmaker in quest to tackle the undruggable

By Annalee Armstrong

Amgen already broke into the “undruggable” market with the approval of Lumakras, but that was just the tip of the iceberg for a pipeline strategy aimed at pursuing targets that were previously considered out-of-reach.

Mission BioCapital pooled together $275 million for its fifth fund, which has already gone toward seven companies and is dedicated to incubating new biotechs and other life sciences startups. The Cambridge and Silicon Valley VC shop also hired 24-year Pfizer veteran Michael Taylor and former Forma Therapeutics CEO Steve Tregay.

After flops, Ironwood starts pipeline rebuild with liver disease deal

By Nick Paul Taylor

Ironwood Pharmaceuticals has advanced plans to build out its pipeline, securing a chance to license Cour Pharmaceuticals’ liver disease candidate CNP-104 after getting a look at early-phase data.

Pfizer adds to Parthenon's $65M war chest to back battle at the tumor barrier

By Emmy Lucas

Pfizer Ventures is one of many investors ponying up $65 million for a new biotech developing anti-cancer therapies to forge an attack on the protective barrier that shields tumors from the immune system.

Aptose inks $408M biobucks deal with Hanmi for access to myeloid inhibitor

By Kyle LaHucik

Aptose Biosciences likes what it sees in a phase 1/2 myeloid kinome inhibitor from Hanmi Pharmaceutical and is paying up to $420 million for the exclusive worldwide rights for the drug. The San Diego biotech snags rights to the South Korean Pharma's inhibitor across all indications.

Allara launches at-home hormone test for diagnosing polycystic ovary syndrome

By Conor Hale

After launching a virtual care platform aimed at PCOS this past summer, Allara is now debuting a diagnostic tool to sift through multiple hormone biomarkers. It hopes to reduce the diagnosis time from an average of three years to as many days.

Turning CAR-T tech against solid tumors by targeting protein fragments in cancer cells

By Angus Liu

A University of Pennsylvania team has developed a new type of engineered immune cell called “peptide-centric” CAR-T that's designed to shrink solid tumors by targeting proteins inside cancer cells. CAR-T cells developed with the technology eradicated neuroblastoma in mouse models and could move into human trials in 2022 or 2023.

ASH: Chasing AbbVie and J&J's Imbruvica, BeiGene's Brukinsa fleshes out competitive leukemia data again

By Angus Liu

After clinical wins in smaller indications, BeiGene has once again posted competitive data for its Brukinsa—this time in the all-important newly diagnosed leukemia—that could further pressure AbbVie and Johnson & Johnson's market leader Imbruvica.

CMS: Healthcare workers must receive their first COVID vaccine by Dec. 5 to continue Medicare, Medicaid participation

By Dave Muoio

To continue participating in Medicare and Medicaid, healthcare facilities must have policies in place to ensure all eligible employees receive an initial COVID-19 shot by Dec. 5 and their second by Jan. 4. CMS said that it expects the requirement to reach more than 17 million healthcare workers across the country.

LabConnect is the leader in innovative central laboratory services for advanced therapies. Far more than typical central laboratory support, only LabConnect offers comprehensive, specialized services customizable to meet the unique needs of your complex clinical trials. Connect with us today.